Erratum
Unfortunately, after publication of this article [1], it was noticed that a funding source was not mentioned. Bristol-Myers Squibb was intended to be included in the ‘Financial Support’ section of the article.
Reference
Patel MA, Kim JE, Theodros D, Tam A, Velarde E, Kochel CM, Francica B, Nirschl TR, Ghasemzadeh A, Mathios D, Harris-Bookman S, Jackson CC, Jackson C, Ye X, Tran PT, Tyler B, Coric V, Selby M, Brem H, Drake CG, Pardoll DM, Lim M. Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. J Immunothera Cancer. 2016;4:28. doi:10.1186/s40425-016-0132-2.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1186/s40425-016-0132-2.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Patel, M.A., Kim, J.E., Theodros, D. et al. Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. j. immunotherapy cancer 4, 74 (2016). https://doi.org/10.1186/s40425-016-0181-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s40425-016-0181-6